Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Radiation plus adjuvant CCNU (1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea) vs CCNU, hydroxyurea and vincristine in the treatment of malignant glioma

Conference · · Int. J. Radiat. Oncol., Biol. Phys.; (United States)
OSTI ID:5339619

Following maximal surgery, 25 patients with malignant glioma were randomized to receive either radiation therapy and CCNU or radiation therapy and CCNU, hydroxyurea, and vincristine. Radiation therapy included 4000 rad to whole brain followed by 1500 rad to the primary. Chemotherapy was either: CCNU alone 130 mg/m/sup 2/ PO every 6 weeks or triple drug chemotherapy given in 6 week cycles of CCNU 90 mg/m/sup 2/ PO (one dose), vincristine 1 mg/m/sup 2/ IV (one dose), and hydroxyurea 1.5 gm/m/sup 2/ PO every 3 days x 7 doses. Thirteen patients received CCNU alone. Of these, 8 are dead, 2 are alive with progressive disease and 3 are alive with stable disease at 10, 22, and 23 months. Median survival is 10 months. Twelve patients received CCNU, vincristine and hydroxyurea. Of these, 8 are dead, 1 is alive with progressive disease and 3 are stable. Median survival is 9.5 months +. Toxicity included nausea, which was common, leukopenia < 3000 in 7 patients and thrombocytopenia in 9 patients. There were no episodes of bleeding or infection attributable to chemotherapy. Although toxicity was tolerable, no additional benefit could be demonstrated for triple agent chemotherapy with CCNU, vincristine and hydroxyurea compared to CCNU alone. Median survival for both groups was similar at 42 to 44 weeks.

Research Organization:
New England Medical Center Hospitals, Boston, MA
OSTI ID:
5339619
Journal Information:
Int. J. Radiat. Oncol., Biol. Phys.; (United States), Journal Name: Int. J. Radiat. Oncol., Biol. Phys.; (United States) Vol. 5:9; ISSN IOBPD
Country of Publication:
United States
Language:
English

Similar Records

Comparison of survival in patients with non-oat cell carcinoma of lung using various types of treatment modalities
Journal Article · Wed Sep 01 00:00:00 EDT 1982 · Int. J. Radiat. Oncol., Biol. Phys.; (United States) · OSTI ID:6579624

Survival of nonsurgically staged patients with negative lymphangiograms who had Stage IIB carcinoma of the cervix treated by pelvic radiation plus hydroxyurea
Journal Article · Sun Apr 14 23:00:00 EST 1985 · Am. J. Obstet. Gynecol.; (United States) · OSTI ID:5676669

Carcinoma of the pancreas: results of irradiation for unresectable lesions
Conference · Thu Jan 31 23:00:00 EST 1980 · Int. J. Radiat. Oncol., Biol. Phys.; (United States) · OSTI ID:5005642